Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration.
Abstract
5P12-RANTES, a chemokine analogue that potently blocks the HIV CCR5 co-receptor, is being developed as both a vaginal and rectal microbicide for prevention of sexual transmission of HIV. Here, we report the first pharmacokinetic data for 5P12-RANTES, following single dose vaginal gel administration in sheep. Aqueous gel formulations containing low (1.24 mg/mL), intermediate (6.16 mg/mL) and high (32.0 mg/mL; suspension-type gel) concentrations of 5P12-RANTES were assessed via rheology, syringeability and in vitro release testing. Following vaginal gel administration in sheep, 5P12-RANTES concentra...
Source: Antimicrobial Agents and Chemotherapy - August 7, 2017 Category: Microbiology Authors: McBride JW, Dias N, Cameron D, Offord RE, Hartley O, Boyd P, Kett VL, Malcolm RK Tags: Antimicrob Agents Chemother Source Type: research
Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse
Objective: To evaluate the efficacy of low concentrations of vaginal estriol gel in postmenopausal women with pelvic static disorders before and after vaginal surgical treatment, assessing vaginal health, sexual function, and quality of life (QoL).
Methods: Women affected by genital prolapse were enrolled. Vaginal health, QoL, and sexual function were investigated at baseline (T0), before surgery (T1), and 13 weeks after surgery (T2). At baseline, participants were randomized 1:1. Women in group A (38 women) were treated daily with vaginal gel containing 50 μg estriol for 12 weeks and women in group B (37 women) did no...
Source: Menopause - July 27, 2017 Category: OBGYN Tags: Original Articles Source Type: research
Monurelle Biogel( ®) vaginal gel in the treatment of vaginal dryness in postmenopausal women.
CONCLUSIONS: Monurelle Biogel(®) vaginal gel applied twice daily for 8 weeks is effective in relieving vaginal dryness and other VA symptoms. Such a clinical meaningful effect persists at least 4 weeks and is supported by an improvement in the vaginal environment. Trial Registration clinicaltrials.gov Identifier: NCT02994342.
PMID: 28657769 [PubMed - as supplied by publisher] (Source: Climacteric)
Source: Climacteric - June 28, 2017 Category: Geriatrics Authors: Nappi RE, Cagnacci A, Becorpi AM, Nappi C, Paoletti AM, Busacca M, Martella S, Bellafronte M, Tredici Z, Di Carlo C, Corda V, Vignali M, Bagolan M, Sardina M Tags: Climacteric Source Type: research
Effect of a pH-Balanced Vaginal Gel on Dyspareunia and Sexual Function in Breast Cancer Survivors Who Were Premenopausal at Diagnosis: A Randomized Controlled Trial.
CONCLUSION: The pH-balanced vaginal gel is not superior to the placebo in improving dyspareunia and overall sexual function.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, https://www.clinicaltrials.gov, NCT00981305.
PMID: 28383379 [PubMed - as supplied by publisher] (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - April 4, 2017 Category: OBGYN Authors: Kim YH, Park S, Lee M, Hahn S, Jeon MJ Tags: Obstet Gynecol Source Type: research
Vaginal use of micronized progesterone for luteal support. A randomized study comparing Utrogestan ® and Crinone® 8%.
CONCLUSION: The outcomes of this study suggest that a vaginal gel with micronized progesterone (Crinone 8%) is the optimal choice at this time for luteal support.
PMID: 28323291 [PubMed - as supplied by publisher] (Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub)
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - March 24, 2017 Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research
Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women
To assess the effect of a 12-day treatment using a vaginal gel based on niosomes containing hyaluronic acid, ß-glucan, alpha-glucan oligosaccharide, Coriolus versicolor, Asian centella, Azadirachta indica and Alo... (Source: BMC Women's Health)
Source: BMC Women's Health - March 16, 2017 Category: OBGYN Authors: Santiago Palacios, Fernando Losa, Dami án Dexeus and Javier Cortés Source Type: research
Predictors of mode of birth and duration of labour following induction using prostaglandin vaginal gel
ConclusionsFollowing IOL using PGE2 vaginal gel at term, both parity and cervical favourability at first review are associated with CS and VD < 24 h. All combinations of parity and MBS at first review predicted fewer CS and greater likelihood of VD < 24 h with a policy of amniotomy once technically possible. (Source: The Australian and New Zealand Journal of Obstetrics and Gynaecology)
Source: The Australian and New Zealand Journal of Obstetrics and Gynaecology - March 12, 2017 Category: OBGYN Authors: Michael Beckmann, Kristen Gibbons, Vicki Flenady, Sailesh Kumar Tags: ORIGINAL ARTICLE Source Type: research
Induction of labour using balloon catheter and prostaglandin gel
ConclusionSimilar to findings in randomised controlled trials and meta‐analyses of IOL methods, we observed more unassisted vaginal births, less blood loss, decreased fetal acidaemia, and a greater likelihood of vaginal delivery within 24 h, with use of balloon catheter as compared to PGE2 vaginal gel. (Source: The Australian and New Zealand Journal of Obstetrics and Gynaecology)
Source: The Australian and New Zealand Journal of Obstetrics and Gynaecology - February 28, 2017 Category: OBGYN Authors: Jacqueline Brown, Michael Beckmann Tags: ORIGINAL ARTICLE Source Type: research
Measuring women ’s experience of induction of labor using prostaglandin vaginal gel
Conclusions The EXIT shows promise as an instrument for assessing women’s experience of IOL. Women undergoing PGE2 vaginal gel IOL report a more positive experience with an early amniotomy rather than with repeat-PGE2. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - December 28, 2016 Category: OBGYN Source Type: research
Measuring women ’s experience of induction of labor using prostaglandin vaginal gel
To describe and examine the EXIT (EXperiences of Induction Tool), and report on the experience of women undergoing PGE2 vaginal gel IOL, who were participants in a randomized controlled trial comparing early amniotomy with repeat-PGE2. (Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology)
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - December 27, 2016 Category: OBGYN Authors: Michael Beckmann, Rachel Thompson, Yvette Miller, Samantha J. Prosser, Vicki Flenady, Sailesh Kumar Tags: Full length article Source Type: research
Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B)
AIDS Research and Human Retroviruses , Vol. 0, No. 0. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - December 12, 2016 Category: Infectious Diseases Authors: Jennifer A. Robinson Mark A. Marzinke Rahul P. Bakshi Edward J. Fuchs Christine L. Radebaugh Wutyi Aung Hans M.L. Spiegel Jenell S. Coleman Lisa C. Rohan Craig W. Hendrix Source Type: research
Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule?
Conclusions Application of 0.005% estriol gel to the vulvar vestibule is effective in correcting menopausal coital pain. This suggests that reduction in sensory vestibular innervation sensitivity is likely to play a pivotal role in the relief of dyspareunia. One limitation of this study is the limited follow-up, but the therapy may be continued for as long as the patients are distressed by their symptoms without estrogen intervention. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - November 2, 2016 Category: OBGYN Source Type: research
A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.
CONCLUSIONS: Daily TFV 1% vaginal gel use in term and near-term pregnancy appears to be safe and produces low serum drug levels.
PMID: 27658440 [PubMed - as supplied by publisher] (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - September 24, 2016 Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
Gynecologic infections and colposcopy findings from a phase 3 efficacy and safety study of a contraceptive vaginal gel compared with nonoxynol-9
Objectives: We aimed to determine safety findings from a Phase 3 study of a contraceptive vaginal gel (L-lactic acid, citric acid and potassium bitartrate). (Source: Contraception)
Source: Contraception - September 14, 2016 Category: OBGYN Authors: M Thomas, K Culwell, B Howard, C Dart Tags: P80 Source Type: research
In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel.
CONCLUSIONS: This is the first report of a human study investigating in vitro HPV inhibition of a carrageenan-based vaginal lubricant with CVL collected after sexual intercourse. We demonstrate excellent efficacy in preventing PsV16 infection.
PMID: 27625046 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - September 9, 2016 Category: Cancer & Oncology Authors: Novetsky AP, Keller MJ, Gradissimo A, Chen Z, Morgan SL, Xue X, Strickler HD, Fernández-Romero JA, Burk R, Einstein MH Tags: Gynecol Oncol Source Type: research
